This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Health Winners & Losers

A few health stocks regained footing Tuesday, with some moving on analyst notes, deals and product news.

Of those on the rebound, NPS Pharmaceuticals (NPSP) ended a collaboration dating back to 2001 with AstraZeneca (AZN - Get Report) that was focused on developing central nervous system disorder treatments. NPS will receive $30 million for its assets related to the collaboration and will use the proceeds for the development of its late-stage pipeline.

NPS shares, which gave up more than 13% Monday on news that George Soros scaled back his stake in the company, climbed back up Tuesday on the latest news, rising 59 cents, or 12%, to $5.34. The stock is a component of the Nasdaq biotechnology index, which was up 5.07, or 0.6%, to 885.41. AstraZeneca was down just 48 cents, or 0.9%, to $51.79.

Also reclaiming ground, Acusphere (ACUS) issued a statement after Monday's close regarding potential Food and Drug Administration action related to approved and commercially available ultrasound contrast agents. The company assured investors that its experimental imaging agent is structurally different from those under scrutiny. The stock gained 18 cents, or 14%, to $1.54.

Brean Murray Carrat analyst Jonathan Ashcoff upgraded Spectrum Pharmaceuticals (SPPI - Get Report) to buy from hold, expecting ozarelix for benign prostatic hyperplasia to demonstrate positive safety and efficacy results in a phase IIb trial and predicting the company will initiate late-stage studies by the end of 2007. Aschoff said in the report that he also expects approval of ISO-Vorin for bone cancer and the filing of a supplemental new-drug application (sNDA) for the drug in colorectal cancer both in the first half of 2008. Shares rose 23 cents, or 5.5%, to $4.39.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ACUS $0.04 0.00%
AZN $28.92 -0.14%
CMN $68.73 2.60%
COO $154.81 1.10%
HNSN $4.01 -0.99%


Chart of I:DJI
DOW 17,756.45 -134.71 -0.75%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs